Genmab A/S
SWB:GE9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Genmab A/S
SWB:GE9
|
DK |
|
M
|
MorphoSys AG
XMUN:MOR
|
DE |
|
ASR Nederland NV
F:A16
|
NL |
|
E
|
Extreme Networks Inc
SWB:EXM
|
US |
|
Paragon Care Ltd
F:PXS
|
AU |
|
P
|
PetroChina Co Ltd
DUS:PC6
|
CN |
|
A
|
Aurum Proptech Ltd
BSE:539289
|
IN |
|
Amcor PLC
ASX:AMCDD
|
CH |
Wall St Price Targets
GE9 Price Targets Summary
Genmab A/S
According to Wall Street analysts, the average 1-year price target for GE9 is 300.89 EUR with a low forecast of 173.67 EUR and a high forecast of 416.64 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is GE9's stock price target?
Price Target
300.89
EUR
According to Wall Street analysts, the average 1-year price target for GE9 is 300.89 EUR with a low forecast of 173.67 EUR and a high forecast of 416.64 EUR.
What is the Revenue forecast for Genmab A/S?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 10%.
What is the Gross Profit forecast for Genmab A/S?
Projected CAGR
7%
The compound annual growth rate for Gross Profit over the next 8 years is 7%.
What is the Operating Income forecast for Genmab A/S?
Projected CAGR
10%
The compound annual growth rate for Operating Income over the next 8 years is 10%.
What is the Pre-Tax Income forecast for Genmab A/S?
Projected CAGR
16%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 16%.
What is the Net Income forecast for Genmab A/S?
Projected CAGR
12%
The compound annual growth rate for Net Income over the next 8 years is 12%.
